2023-507203-55-00
已完成
1 期
A three part randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and preliminary efficacy of an inhaled (nebulized) phage cocktail in healthy subjects and in patients with chronic colonization of the lung with Pseudomonas aeruginosa
Charite Research Organisation GmbH1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年8月8日最近更新:
概览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Charite Research Organisation GmbH
- 入组人数
- 50
- 试验地点
- 1
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Scientific Service
Scientific
Charite Research Organisation GmbH
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.2024-512722-28-00Bioprojet Pharma161
尚未招募
1 期
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus2025-522551-25-00AstraZeneca AB28
招募中
1 期
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)2023-507700-32-00Peaches Biotech S.L.50
招募中
1 期
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers2023-504324-26-00Remab Therapeutics S.L.40
已完成
1 期
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.2023-503945-78-00Bioprojet Pharma75